Skip to main navigation
Skip to main content
About Us
Overview
Leadership
Board of directors
Scientific advisory board
Corporate Responsibility
Contact us
FORCE
TM
Platform
Overview
Scientific publications & presentations
Pipeline
Overview
zeleciment rostudirsen (DYNE-251)
zeleciment basivarsen (DYNE-101)
DYNE-302
Physicians
Patients
Commitment
Clinical trials
DMD stories
DM1 stories
FSHD stories
Resources
Investors & Media
Company overview
News, publications & events
Stock information
Corporate governance
Financials & filings
IR resources
Culture & Careers
Our culture & values
Hear from our Dynamos
Competitive benefits
Open positions
Open navigation
About Us
FORCE
TM
Platform
Pipeline
Physicians
Patients
Investors & Media
Culture & Careers
Overview
Leadership
Board of directors
Scientific advisory board
Corporate Responsibility
Contact us
about-us
Overview
Scientific publications & presentations
force™-platform
Overview
zeleciment rostudirsen (DYNE-251)
zeleciment basivarsen (DYNE-101)
DYNE-302
pipeline
physicians
Commitment
Clinical trials
DMD stories
DM1 stories
FSHD stories
Resources
patients
Company overview
News, publications & events
Stock information
Corporate governance
Financials & filings
IR resources
investors--media
Our culture & values
Hear from our Dynamos
Competitive benefits
Open positions
culture--careers
Stay in Touch
info@dyne-tx.com
781.786.8230
781.786.8230
linkedin.com
twitter.com
facebook.com
youtube.com
Poised to address unmet need in neuromuscular diseases and
positioned for growth
FAQs
Email Alerts
Contact IR
Contact IR
Contact IR
Name
Email
Subject
Comments
Leave this field blank
Print
Contact IR
RSS
Email Alerts
You are now leaving
the Dyne Therapeutics corporate website
Continue
Stay on page
Open navigation
Open navigation